TEST:

oncoReveal™ Fusion LBx Panel

"Pillar Biosciences said Wednesday that more of its OncoReveal next-generation sequencing panels will be offered by Illumina in an expansion of the companies’ existing partnership...The deal includes the OncoReveal Essential MPN, Myeloid, Multi-Cancer with CNV and Fusion panel, and BRCA1 and BRCA2 plus CNV panel, which will be available as part of validated workflows on the MiSeq i100 sequencer launched last week."

"Pillar Biosciences, Inc. has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing, using rapid, Next Generation Sequencing (NGS)-based liquid biopsy tumor profiling panels for detection of genetic cancer variants, with an initial focus on European markets and the UK...The partnership aims to rapidly identify tumors with clinically actionable genomic alterations via liquid biopsy profiling and intends to support faster diagnostic testing by increasing the local availability of plasma-based tumor profiling at leading clinical laboratories....The work will initially leverage Pillar Biosciences oncoReveal Core LBx, Essential LBx, and Fusion LBx research-use-only (RUO) liquid biopsy kitted NGS panels."